Chief Executive Officer
Matt Tindall has more than two decades of healthcare experience spanning general management, corporate development, strategy consulting, digital marketing and commercial operations. Prior to Omicia, he served as the general manager of the Consumer Solutions division of IMS Health, a leading global information and technology services company in the healthcare industry.
During his tenure at IMS Health, Matt built an industry-leading SaaS business in the digital health space, authored multiple new intellectual property filings, led the acquisition and integration of a global technology company and assisted in the company’s transition to a become a public company (NYSE: IMS Health).
Prior to IMS Health, Matt was VP Marketing at Digitas Health New York (a subsidiary of Publicis Groupe) leading commercial marketing activities for Pfizer, BMS and Boehringer Ingelheim, worked in strategic business development for Celera Genomics, led a cardiovascular business development team focused on the development of novel gene therapy, cell therapy and biomaterial products at Genzyme Corporation and co-founded and managed a start-up biopharmaceutical company named Sarentis Therapeutics. Matt received his B.S. in Human Physiology from Lyman Brigg’s College at Michigan State University and his M.B.A. from the University of Texas at Austin.
Martin G. Reese, Ph.D.
and Chief Scientific Officer
Dr. Martin Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Omicia, Martin served as Vice President of Discovery Informatics for ValiGen.
Edward S. Kiruluta
Chief Technology Officer
Edward Kiruluta is responsible for product development, operations, and IT at Omicia. Previously Edward was the Vice President of Development at Symyx Technologies, Inc., where he was responsible for the development of Symyx Notebook.
Paul Billings, M.D., Ph.D.
Chief Medical Officer
Dr. Paul Billings serves as Chief Medical Officer at Omicia. Prior to joining Omicia, Dr. Billings was CMO at Life Technologies, acquired by Thermo Fisher Scientific, Inc. (NYSE: TMO). Before that he was founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital. Dr. Billings served as President, CEO and Director of CELLective Dx Corporation.
Chief Operating Officer
Adam Grant leads all post-sales teams and operations at Omicia, including implementation, account management, customer service, CRM, reporting, and other systems and tools. He is responsible for scaling teams, processes, and systems to retain, engage, and drive revenue from new and existing customers. Prior to Omicia, Adam held executive roles at PokitDok and Practice Fusion.
Charlene Son Rigby
Vice President, Products & Strategy
Charlene Son Rigby is responsible for product management and marketing at Omicia. Charlene has spent her career building businesses at the intersection of data, technology and life sciences. Previous to Omicia, she was responsible for all go-to-market activities at Metamarkets, a big data analytics startup.
Vice President, Business Development
Mathias Klozenbuecher is responsible for all Business Development activities at Omicia. His responsibilities include 3rd party partnerships, strategic alliances, licensing and co-development opportunities.
In addition to Matt Tindall and Martin Reese, Omicia’s board members are:
John Stuelpnagel, D.V.M.
Co-founder, Chairman of the Board of Directors
Dr. John Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function.
John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008.
Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
Mike A. Aicher
Board of Directors
Mike co-founded and served as National Genetics Institute’s (NGI) CEO since 1991. NGI became a wholly owned subsidiary of Laboratory Corporation of America (NASDAQ: LH) in 2000, where he held various positions.
Board of Directors
Mr. Buchanan co-founded the investment firm of Buchanan Investments, Inc. in 1998 with his father, Mike. Together, they have founded, invested in and raised equity and debt capital for numerous companies, including DM&E Railroad, Central Montana Resources, Opti Canada, White Oak Resources, AlphaClone, TabletCommand, Gensys Software, Tri Alpha Energy, OneSun Solar, and numerous other private companies.
Board of Directors
Matt Posard has over 25 years of general management and commercial experience in the life sciences, molecular diagnostics and genomics industry. Mr. Posard held influential leadership roles with market leading companies including Illumina, Trovagene, Biosite / Alere, and Gen-Probe.